GKOS · Glaukos Corporation
Price
Snapshot
50 fields · last close| Market Cap | $14.60B |
| P/E | — |
| Float | 57.09M |
| Beta | 0.67 |
| Volatility 30D | 91.1% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 59.8 |
| Price | 222.20 |
| Change | −9.93% |
| Prev Close | 246.70 |
| Open | 237.18 |
| Day Low | 235.27 |
| Day High | 255.19 |
| Avg Vol | 3 |
| Avg $ Vol | $673.8M |
| 52W High | 248.75 |
| 52W Low | 80.91 |
| 52W Pos | 84.2% |
| From High | −10.67% |
| From Low | +174.64% |
| Max DD 1Y | −28.39% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +17.85% |
| SMA 50 | +25.81% |
| SMA 200 | +55.11% |
| RSI (14) | 80.7 |
| Vol 90D | 61.5% |
| Vol 1Y | 56.8% |
| 1Y Range | 81–249 |
| Daily bars | 549 |
| Perf Week | +35.98% |
| Perf Month | +52.67% |
| Perf Quarter | +44.28% |
| Perf Half Y | +82.38% |
| Perf Year | +182.30% |
| Perf YTD | +100.69% |
| Prev Day | −9.93% |
| Clavix | C+ |
| Debt / Eq | 0.01 |
| Curr Ratio | 4.69 |
| Int Cover | -74.1× |
| FCF Margin | −4.4% |
| Rev Growth | +32.3% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 47 / 49 |
Clavix risk grade
regraded every trading dayGKOS grades C+, 59.8 of 100. Steadiest on Macro Resilience (66), most exposed on Price Stability (35, fragile). 0 of the 4 weighted dimensions sit above the Health Care median. Ranks 47 of 49 in Health Care by Clavix score.
How rough the ride is
| GKOS | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.67 | 0.79 |
| 30-day realized volatilityannualized, from daily closes | 91.1% | 36.1% |
| Max drawdown, past yearworst peak-to-trough fall | −28.4% | — |
| Typical daily movemedian absolute daily change | 1.54% | — |
| Days beyond ±3%of the last 252 sessions | 54 (21%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| GKOS | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.67 | 0.79 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 51% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| GKOS | |
|---|---|
| 1 week | +36.0% |
| 1 month | +52.7% |
| Year to date | +100.7% |
| 1 year | +182.3% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| GKOS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 24 Sep |
| Average score0 most bearish, 100 most bullish | 75 |
| Bullish · bearisharticles above 60 · below 40 | 28 · 0 |
| Directionarticles whose tone is improving vs worsening | 28 ↑ 0 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| GKOS | |
|---|---|
| Revenue growthyear over year | +32.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openMarketBeat reports that 16 investment firms cover Glaukos and that the group has a consensus rating of "Moderate Buy." The excerpt says one firm rates the stock a sell and one rates it a hold, but cuts off before detailing the other 13 ratings.
Glaukos reported record Q3 2026 revenue of US$211.03 million and positive basic earnings per share of US$0.034142, and raised its full-year sales outlook. Shares rose 33.65% in the first full trading session after the results.
Glaukos raised its 2026 sales forecast to $775 million-$785 million and set a preliminary 2027 target of $1 billion; third-quarter sales rose 58% to about $211 million, and shares gained roughly 31% in midday trading. U.S. glaucoma and corneal health products supplied all the gain over the second quarter, but international glaucoma sales fell about 9% and GAAP operating income was barely positive after excluding roughly $20 million in legal costs from adjusted results.
Glaukos raised its 2026 sales forecast to $775 million-$785 million and set a preliminary 2027 sales target of $1 billion. Third-quarter sales jumped 58% to $211.0 million, but the article says profit is thinner than the adjusted figures suggest.
Wells Fargo & Company raised its Glaukos price target from $178 to $226 and gave the stock an "overweight" rating, meaning it expects the stock to outperform the market. The brief article reports no new company financial or operating developments, so no substantive business implications can be drawn.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| SOLV | Solventum Corporation | B+ | $15.21B | 10.05 | 0.76 | Compare |
| BTSG | Brightspring Health Services Inc | B | $13.89B | 37.97 | 1.79 | Compare |
| BAX | Baxter International Inc. | B | $13.71B | — | 0.62 | Compare |
| PEN | Penumbra, Inc. | A+ | $12.71B | 79.35 | 0.65 | Compare |
| COO | The Cooper Companies, Inc. | B | $12.25B | 20.28 | 0.79 | Compare |
| DVA | DaVita Inc | B | $12.12B | 12.75 | 0.82 | Compare |
| ZBH | Zimmer Biomet Holdings, Inc. | B+ | $18.03B | 26.03 | 0.46 | Compare |
| MOH | Molina Healthcare Inc | B | $11.82B | 22.99 | 0.69 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.